SI-BONE (SIBN) Stock Analysis & AI Equity Report
SI-BONE (SIBN) overview
SI-BONE (SIBN) stock analysis and AI equity research. For financial year 2025, Valuatum's model shows revenue of USD 201m and operating profit of USD -22.3m; the year-end share price was 19.72 USD and market capitalisation was USD 861m. SI-BONE is covered by Valuatum but does not yet have a published AI equity report. Generate a fresh report to get SI-BONE's valuation, segment value analysis, reverse valuation, financial forecasts, key ratios, risks and catalysts.
Key metrics & valuation multiples
About SI-BONE
SI-BONE develops and markets implant systems and instruments for minimally invasive surgery involving the sacroiliac joint and pelvic anatomy. Its portfolio includes titanium implants and implantable bone products used in procedures addressing sacroiliac joint dysfunction, pelvic trauma, and certain spinal conditions. The company serves orthopedic and spine surgeons and patients through clinician training, product support, and sales channels in the United States and internationally.
Generate the SI-BONE report
SI-BONE is on Valuatum's coverage list, but a full AI equity report hasn't been generated yet. Order one now for the complete company value map, reverse valuation, risk & catalyst analysis, and financial statements and estimates — plus a downloadable PDF.
Sources & methodology
Financial figures are sourced from Valuatum's financial model for SI-BONE and represent financial year 2025. See the methodology for the full Valuatum AI equity research framework.
Disclaimer: This is an AI-generated research material for informational purposes only. It is not investment advice or a buy/sell recommendation. Always perform your own analysis. Valuatum Oy, Helsinki, Finland.
Analyst reports on SI-BONE
Each report here is this company's Valuatum report re-run with an analyst's own assumptions and published under their name. They are ordered by a score out of five: what other analysts felt the work added over the engine's default report.